Loading IRTC detail
Loading ticker data...
Loading IRTC detail
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States.
It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products.
The company was incorporated in 2006 and is headquartered in San Francisco, California.
Chart data unavailable
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients.
MSP Recovery (NASDAQ: MSPR - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Profitability This table compares MSP Recovery and iRhythm
iRhythm rides strong volume growth, AI-driven innovation and primary care expansion, but reimbursement pressure and rising competition cloud the outlook.
Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio ® ambulatory ECG portfolio. 1,2 Chief Medical Officer Mintu Turakhia, MD, MS, delivered the 57th Annual Louis F.
Assenagon Asset Management S.A. grew its stake in iRhythm Technologies (NASDAQ: IRTC) by 189.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 225,205 shares of the company's stock after buying an additional 147,329 shares during the quarter. Assenagon Asset
RTW Investments acquired 1,181,990 IRTC shares during Q4 2025, with an estimated position value of $210 million based on the 13F reported at quarter-end. The position represents 2.1% of RTW's 13F reportable AUM.
Cinctive Capital Management LP acquired a new stake in shares of iRhythm Technologies (NASDAQ: IRTC) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 28,044 shares of the company's stock, valued at approximately $4,823,000. Cinctive Capital Management LP owned about 0.09%
SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, is pleased to announce the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten brings decades of strategic leadership in healthcare, reinforcing iRhythm's commitment to innovation, operational excellence, and long-term growth.
United Treatment Centers (OTCMKTS:POTN - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership. Analyst Ratings This is a summary of
iRhythm Technologies (NASDAQ: IRTC - Get Free Report) CEO Quentin Blackford sold 25,540 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $135.42, for a total transaction of $3,458,626.80. Following the completion of the transaction, the chief executive officer owned 186,126 shares in the
Artisan Partners Limited Partnership decreased its position in shares of iRhythm Technologies (NASDAQ: IRTC) by 6.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,567,513 shares of the company's stock after selling 173,328 shares during the quarter. Artisan Partners Limited
The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to performance for both the quarter and year. Management highlighted strong demand for high-speed optical components supporting AI-driven data center growth, alongside improving margins.
iRhythm Holdings, Inc. (IRTC) Q4 2025 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.01 per share a year ago.
